5th Edition of International Heart Congress
June 24-26, 2027 | Hybrid Event
Personalized Cardiology and Precision Medicine
Personalized cardiology and precision medicine are revolutionizing heart disease treatment by tailoring care to each individual based on their unique genetic makeup, lifestyle, and environment. This approach allows cardiologists to select the most effective therapies for patients, increasing the likelihood of successful outcomes and minimizing adverse effects. By utilizing advanced diagnostic tools, such as genetic testing and imaging, personalized cardiology helps identify risk factors early, enabling timely interventions. In the realm of precision medicine, therapies are designed to target specific pathways involved in the patient’s condition, ensuring more efficient treatment and improving the overall prognosis for heart disease patients.
John R Doty
Intermountain Medical Center, United States
Agustin Joison
Cordoba Catholic University, Argentina
Thomas J Webster
Brown University, United States
Uwe Peter Tigor
Auxilius Pharma, United States
Sergey Suchkov
N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Bijoy Krishna Banik
National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, IndiaSubmit your abstract Today
Title : Healing a broken heart: One nano beat at a time
Thomas J Webster, Brown University, United States
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Antidiabetic agents – From treating diabetes to providing positive cardiovascular outcome
Syed Raza, Awali Hospital, Bahrain